Sigma-Aldrich Inks Transcriptome Licensing Deal with Rubicon Genomics
Goal is to commercialize TransPlex technology.!--h2>
Sigma-Aldrich signed an exclusive licensing agreement with Rubicon Genomics to further develop and commercialize their TransPlex™ whole transcriptome amplification (WTA) technology. TransPlex can be used to amplify total RNA from a variety of sample sources, such as animals, plants, and microorganisms, according to Sigma. Under the terms of the agreement, Rubicon retains all rights to TransPlex for molecular diagnostics.
TransPlex WTA creates a cDNA library from the isolated RNA template and then amplifies the library in a single PCR reaction. The TransPlex reagents and protocols, optimized to ensure a linear representation of all expressed genes and exons, allow RNA samples to be amplified 1,000–10,000 fold in less than four hours, explains John Langmore, vp of commercial development at Rubicon.